Updated
Updated · GlobeNewswire · Aug 3
Single-Cell Multiomics Market to Reach $18.20 Billion by 2035 as AI and Genomics Lift Demand
Updated
Updated · GlobeNewswire · Aug 3

Single-Cell Multiomics Market to Reach $18.20 Billion by 2035 as AI and Genomics Lift Demand

1 articles · Updated · GlobeNewswire · Aug 3

Summary

  • The market is projected to grow from $2.99 billion in 2025 to $18.20 billion by 2035, implying a 19.81% CAGR as drug discovery, biomarker work and precision medicine adopt higher-resolution cellular analysis.
  • North America held a 41.85% revenue share in 2025, with the U.S. market seen rising from $0.98 billion to about $5.08 billion by 2035, while Asia Pacific is forecast to expand the fastest.
  • Single-cell genomics led products with a 34.20% share in 2025, but proteomics is expected to grow fastest at a 23.16% CAGR as researchers widen multiomics use cases.
  • Oncology accounted for 38.90% of applications and pharmaceutical and biotechnology companies for 39.10% of end users in 2025, underscoring cancer research and commercial R&D as the market's main demand base.
  • Droplet-based microfluidics dominated technology platforms with a 56.30% share, while spatial-omics platforms are forecast to post the fastest growth at a 24.50% CAGR, reflecting rising demand for tissue-level resolution.

Insights

With AI and spatial omics colliding, who will dominate the $18 billion race to map human cells before the decade ends?
As biotech giants swallow up smaller innovators, will rapid market consolidation stifle the next major breakthrough in spatial biology?
Could the massive data complexity of single-cell multiomics stall its leap from the research lab to life-saving clinical diagnostics?